Edit
MSNBC
03 Oct 2013
Eli Lilly announces a new share repurchase program and its plans to launch new drugs next year. Read the full press release here. ... Advertise. Advertise. Advertise ... U.S ... U.S ... Business outlook ... Later in the decade, Bio-Medicines could provide significant revenue growth through a combination of launches of new molecules currently in Phase 3 development, including solanezumab, evacetrapib, baricitinib, ixekizumab, tabalumab and edivoxetine ... ....(size: 9.8Kb)
Edit
StreetInsider
03 Oct 2013
Tweet Send to a Friend. Get Alerts LLY Hot Sheet. Price. $50.54 --0%. Revenue Growth %. +5.9%. Financial Fact.. Dividends paid per share. 0.49. Today's EPS Names.. STZ, IDT, CMTL, More ... (NYSE ... * U.S ... Later in the decade, Bio-Medicines could provide significant revenue growth through a combination of launches of new molecules currently in Phase 3 development, including solanezumab, evacetrapib, baricitinib, ixekizumab, tabalumab and edivoxetine ... ....(size: 10.0Kb)
Edit
Lilly details progress on achieving strategic business goals and its advancing pipeline to investment community
Seeking Alpha03 Oct 2013
INDIANAPOLIS, Oct ... The company also announced a new share repurchase program that will return an additional $5 billion to shareholders over time ... U.S ... U.S ... Business outlook ... After the U.S ... Later in the decade, Bio-Medicines could provide significant revenue growth through a combination of launches of new molecules currently in Phase 3 development, including solanezumab, evacetrapib, baricitinib, ixekizumab, tabalumab and edivoxetine ... C-LLY....(size: 13.6Kb)
Edit
Lilly details progress on achieving strategic business goals and its advancing pipeline to investmen
Stockhouse03 Oct 2013
INDIANAPOLIS, Oct ... The company also announced a new share repurchase program that will return an additional $5 billion to shareholders over time ... U.S ... U.S ... Business outlook ... After the U.S ... Later in the decade, Bio-Medicines could provide significant revenue growth through a combination of launches of new molecules currently in Phase 3 development, including solanezumab, evacetrapib, baricitinib, ixekizumab, tabalumab and edivoxetine....(size: 13.7Kb)
Edit
Lilly details progress on achieving strategic business goals and its advancing pipeline to investment community (Eli Lilly and Company)
noodls03 Oct 2013
(Source. Eli Lilly and Company). INDIANAPOLIS, Oct ... The company also announced a new share repurchase program that will return an additional $5 billion to shareholders over time ... U.S ... U.S ... Later in the decade, Bio-Medicines could provide significant revenue growth through a combination of launches of new molecules currently in Phase 3 development, including solanezumab, evacetrapib, baricitinib, ixekizumab, tabalumab and edivoxetine....(size: 14.2Kb)
Edit
Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceutical's Brintellix Has Blockbuster Potential
PR Newswire01 Aug 2013
Download image. Decision Resources Logo. (PRNewsFoto/Decision Resources). BURLINGTON, Mass., Aug ... (Logo ... The launch of Brintellix and two other emerging antidepressants by 2022—Eli Lilly's edivoxetine and Forest Laboratories/Pierre Fabre's Fetzima—will be insufficient to counteract this decline; edivoxetine and Fetzima will together reach just under $1 billion in sales across the major markets by 2022 ... Simorellis, Ph.D ... ....(size: 4.6Kb)
Edit
Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives
PR Newswire22 Oct 2012
Google. . . . , Oct. 22, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.. Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives ... Summary ... Scope ... Reasons to buy ... 1 Table of Contents ... 3.6 Revenue 21 ... 6.3.3 LY-2216684 (edivoxetine) 84....(size: 23.9Kb)
Edit
PR Newswire
20 Sep 2011
. , Sept. 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. ... •Edivoxetine (LY2216684; Eli Lilly) ... - Edivoxetine forecast 2010–20 ... Edivoxetine (LY2216684; Eli Lilly) sales forecast for depression in the seven major markets ($m), 2010–20 ... Edivoxetine (LY2216684; Eli Lilly) sales forecast for depression in the seven major markets ($m), 2010–20 ... US....(size: 20.3Kb)
Edit
Business Wire
04 Jul 2011
DUBLIN - Research and Markets (http.//www.researchandmarkets.com/research/1508d6/product_profiles) has announced the addition of the "Product Profiles ... Highlights ... ... Pipeline Product Profiles Viibryd (vilazodone; Forest) Lu AA21004 (Lundbeck/Takeda) TC-5214 (Targacept/AstraZeneca) Levomilnacipran (F2695; Forest/Pierre Fabre) Edivoxetine (LY2216684; Eli Lilly) Vyvanse (lisdexamfetamine; Shire) Other drugs in development for depression ... ....(size: 6.9Kb)
Edit
Business Wire
27 Jun 2011
Patents for many leading depression treatment brands to expire between 2012-2015 Lexapro (escitalopram) noted for its tolerability and high efficacy compared with other antidepressant brands Analysis of available clinical data for depression treatments included ... Product Profiles. Depression - Next generation vies for second-line patients ... Brands profiled include ... Viibryd; Lu AA21004; TC-5214; Levomilnacipran; Edivoxetine and Vyvanse ... ....(size: 8.1Kb)
Edit
PR Newswire
27 Jun 2011
. , June 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.. Product Profiles. Depression - Next generation vies for second-line patients. http.//www.reportlinker.com/p0564398/Product-Profiles-Depression---Next-generation-vies-for-second-line-patients.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... Edivoxetine (LY2216684; Eli Lilly)....(size: 21.9Kb)
